Reproducibility In Therapeutic Research – ReiTheR
Reproducibility in therapeutic research
Ideally, medical practitioners and health policy analysts feel more confident when the results and conclusions of therapeutic research can be replicated. Although this is rarely promoted or rewarded science moves forward when researchers verify other researchers’ results. However, there is growing alarm about results that cannot be reproduced. In response, scientists have launched various replication initiatives to assess the robustness of published research.
General objectives and main issue
In the context of a growing interest in data-sharing in medicine, this project aims 1/ to perform systematic re-analyses of Randomised Controlled Trials (RCTs) in order to assess their reproducibility and 2/ to develop a tool to identify transparent and reproducible scientific practices.
We will critically appraise all initiatives for data sharing in medicine and identify the impact on therapeutic research of data sharing platforms.
A random sample of 62 RCTs will be selected and re-analyzed. Results of these re-analyses will be compared with results of the initial analysis.
The same method will be applied for all new drugs submitted to the European Medicine Agency in order to provide a practical information for drug regulation.
A scale for quoting useful data sharing and reproducibility will be developed.
Work in progress
France is involved in the G7 initiative that call for open practices in Science. This project will provide empirical data on such practices and their usefulness.
Work in progress
In the context of the growing interest in data-sharing in medicine, this project aims 1/ to perform systematic re-analyses of Randomised Controlled Trials (RCTs) in order to assess their reproducibility and 2/ to develop a tool to identify transparent and reproducible scientific practices.
We will critically appraise all initiatives for data-sharing in medicine and identify all platforms that enable RCT data to be shared. A random sample of 62 RCTs will be selected and re-analysed. The results of these re-analyses will be compared with the results of the original analyses. The same method will be applied for all new drugs submitted to the European Medicine Agency in order to replicate results and to provide practical information for drug regulation. The impact of certain contextual factors on reproducibility will be explored. A scale for scoring the sharing and reproducibility of useful data will be developed.
France is involved in the G7 initiative calling for open practices in Science. This project will provide empirical data on these practices and their usefulness.
Project coordination
Florian NAUDET (CIC RENNES)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
CIC CIC RENNES
Help of the ANR 254,166 euros
Beginning and duration of the scientific project:
- 36 Months
